Westover Capital Advisors LLC Has $1.69 Million Stake in Medpace Holdings, Inc. (NASDAQ:MEDP)

Westover Capital Advisors LLC decreased its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 6.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,094 shares of the company’s stock after selling 356 shares during the quarter. Westover Capital Advisors LLC’s holdings in Medpace were worth $1,692,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of MEDP. Private Advisor Group LLC raised its stake in Medpace by 29.7% during the third quarter. Private Advisor Group LLC now owns 1,448 shares of the company’s stock worth $483,000 after acquiring an additional 332 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in Medpace by 17.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,243 shares of the company’s stock worth $412,000 after acquiring an additional 185 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its stake in shares of Medpace by 80.3% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 2,422 shares of the company’s stock valued at $808,000 after buying an additional 1,079 shares during the period. US Bancorp DE increased its stake in shares of Medpace by 59.3% in the third quarter. US Bancorp DE now owns 8,100 shares of the company’s stock valued at $2,704,000 after buying an additional 3,016 shares during the period. Finally, Stephens Inc. AR increased its stake in shares of Medpace by 16.4% in the third quarter. Stephens Inc. AR now owns 717 shares of the company’s stock valued at $239,000 after buying an additional 101 shares during the period. Institutional investors and hedge funds own 77.98% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Robert W. Baird upped their price objective on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research note on Monday, January 27th. Seven investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, Medpace presently has an average rating of “Hold” and a consensus price target of $381.44.

Medpace Stock Performance

NASDAQ:MEDP opened at $319.17 on Tuesday. The company has a market capitalization of $9.72 billion, a PE ratio of 25.27, a P/E/G ratio of 3.81 and a beta of 1.36. The company has a 50 day simple moving average of $342.26 and a two-hundred day simple moving average of $344.70. Medpace Holdings, Inc. has a fifty-two week low of $302.01 and a fifty-two week high of $459.77.

Medpace (NASDAQ:MEDP) last released its earnings results on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, beating analysts’ consensus estimates of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. Research analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.